Lyme Disease in the United States: Emerging Trends and Public Health Challenges

Abstract

Lyme disease, caused by the spirochete Borrelia burgdorferi and transmitted through the bite of infected blacklegged ticks, remains the most prevalent vector-borne disease in the United States. Over the past few decades, its incidence has risen significantly, with geographic expansion beyond traditional endemic areas of the Northeast and Midwest into new regions. This article explores the emerging trends in Lyme disease epidemiology, including the influence of climate change, land use patterns, and co-infections on disease spread. It also examines public health challenges such as underreporting, diagnostic difficulties, and the lack of a human vaccine. A comprehensive literature review, situational analysis, and discussion of current interventions are provided, alongside recommendations for improved surveillance, prevention strategies, and public education. Addressing the growing burden of Lyme disease requires interdisciplinary approaches and innovative solutions to mitigate its impact on public health.

Introduction

Lyme disease, first identified in the 1970s in Lyme, Connecticut, has evolved from a localized ailment to a significant public health concern across the United States. Transmitted primarily by the blacklegged tick (Ixodes scapularis) in the eastern and central regions, and the western blacklegged tick (Ixodes pacificus) on the Pacific Coast, the disease is caused by the bacterium Borrelia burgdorferi. Early symptoms include fever, fatigue, and the characteristic erythema migrans rash, but untreated cases can progression to severe neurological, cardiac, and joint complications. The Centers for Disease Control and Prevention (CDC) estimates that approximately 476,000 Americans are diagnosed with Lyme disease annually, a figure that likely underrepresents the true burden due to misdiagnosis and underreporting (CDC, 2025a).

The epidemiology of Lyme disease is dynamic, influenced by environmental, ecological, and human factors. Climate change has extended tick habitats northward and into higher altitudes, while urbanization and land use changes have brought humans into closer contact with tick populations. Additionally, the recognition of co-infections such as babesiosis and anaplasmosis, often transmitted by the same ticks, complicates diagnosis and treatment. Public health challenges are compounded by the absence of a commercially available human vaccine, limited public awareness in newly affected regions, and controversies surrounding chronic Lyme disease. This article aims to synthesize current knowledge on Lyme disease trends and challenges, providing a foundation for strategic public health responses.

Situational Analysis

The incidence of Lyme disease in the United States has increased dramatically over the past few decades. According to the CDC, reported cases have risen from approximately 10,000 in 1995 to over 30,000 annually in recent years, with an adjusted estimate of 476,000 cases per year based on insurance claims data (CDC, 2025a; Schwartz et al., 2021). The majority of cases are concentrated in the Northeast, Mid-Atlantic, and upper Midwest, with states like Pennsylvania, New York, and Connecticut reporting the highest numbers. However, emerging data indicate a geographic expansion into the South and West, areas previously considered low-risk (EPA, 2025). This shift is attributed to changing environmental conditions and increased host and vector populations, particularly white-tailed deer and small mammals that serve as reservoirs for Borrelia burgdorferi.

Climate change plays a pivotal role in this expansion. Warmer temperatures and milder winters extend the tick life cycle, allowing for longer periods of activity and reproduction. Studies have shown that regions with increased average temperatures and humidity—conditions favorable for tick survival—correlate with higher Lyme disease incidence (EPA, 2025). Additionally, land use changes, such as suburban development into forested areas, have created fragmented habitats that favor tick-host interactions. Urban green spaces and recreational areas further heighten exposure risks for human populations (Robinson et al., 2023).

Another emerging concern is the rise of co-infections. Ticks that transmit Lyme disease often carry other pathogens, including Babesia microti (causing babesiosis) and Anaplasma phagocytophilum (causing anaplasmosis). Recent reports highlight the increasing prevalence of babesiosis in the Mid-Atlantic, a region previously less affected, signaling a growing public health threat (DVIDS, 2025). Co-infections can exacerbate clinical outcomes, complicate diagnosis due to overlapping symptoms, and require distinct treatment approaches, posing additional challenges for healthcare providers.

Surveillance data also reveal disparities in case reporting and diagnosis. The CDC updated its case definition in 2022 to improve accuracy, yet underreporting remains a significant issue, particularly in non-endemic areas where awareness among healthcare providers and the public is low (CDC, 2024). Commercial claims data suggest that many cases are managed in outpatient settings without formal reporting, skewing official statistics (Schwartz et al., 2021). Furthermore, the lack of a gold-standard diagnostic test for early-stage Lyme disease often leads to misdiagnosis, delaying treatment and increasing the risk of chronic complications.

Literature Review

The body of research on Lyme disease in the United States is extensive, covering epidemiology, ecology, clinical management, and public health policy. Early studies by Steere et al. (1977) established the clinical and microbiological foundation of the disease, identifying Borrelia burgdorferi as the causative agent and ticks as the primary vector. Subsequent research has focused on the ecological drivers of disease spread, with numerous studies linking tick distribution to host availability and environmental conditions. For instance, Ostfeld et al. (2006) demonstrated that biodiversity loss in fragmented habitats increases Lyme disease risk by reducing predator populations that control small mammal hosts.

Recent literature emphasizes the role of climate change in altering Lyme disease epidemiology. Brownstein et al. (2005) modeled the northward expansion of tick habitats in response to rising temperatures, a trend confirmed by contemporary surveillance data (EPA, 2025). Additionally, Robinson et al. (2023) explored the relationship between land cover and Lyme disease incidence, finding that areas with high greenness and forest edge density—common in suburban settings—correlate strongly with increased case rates. These findings underscore the intersection of environmental and human behavioral factors in disease transmission.

On the clinical front, research highlights ongoing challenges in diagnosis and treatment. Serological testing, while widely used, often yields false negatives in early infection stages, prompting calls for improved diagnostic tools (Marques, 2015). The controversy surrounding chronic Lyme disease—characterized by persistent symptoms despite treatment—remains a debated topic. While some studies attribute these symptoms to post-treatment Lyme disease syndrome (PTLDS), others suggest possible persistent infection or immune dysregulation (LymeDisease.org, 2025). This lack of consensus complicates patient care and fuels public mistrust in medical guidelines.

Public health interventions have also been a focus of scholarly inquiry. Kugeler et al. (2015) evaluated community-based prevention strategies, such as tick repellent use and landscape modification, finding variable efficacy due to inconsistent public adoption. The absence of a human vaccine, despite successful veterinary vaccines for dogs, is another critical gap in prevention. Historical attempts, such as the LYMErix vaccine introduced in the late 1990s, were withdrawn due to poor market uptake and legal concerns, highlighting barriers to vaccine development and public acceptance (Science Friday, 2025).

Finally, emerging studies on co-infections reveal a complex epidemiological landscape. Diuk-Wasser et al. (2016) documented the increasing prevalence of babesiosis and anaplasmosis in Lyme-endemic areas, noting that co-infections often result in more severe illness and diagnostic confusion. These findings call for integrated surveillance systems that account for multiple tick-borne pathogens, a priority for future research and policy.

Discussion

The rising incidence and geographic expansion of Lyme disease in the United States reflect a confluence of ecological, climatic, and societal factors. Climate change, as a primary driver, has altered tick biology and distribution, pushing the disease into new territories. This trend is particularly concerning in the context of global warming, as sustained temperature increases are projected to further expand tick habitats (EPA, 2025). Public health systems in newly affected regions, such as the South and parts of the West, are often unprepared for this emerging threat, lacking the infrastructure and awareness necessary for effective response.

The role of human behavior and land use cannot be understated. Suburban sprawl into forested areas creates ideal conditions for human-tick contact, while recreational activities in tick-endemic areas heighten exposure risks. These patterns underscore the need for targeted education campaigns that address both personal protective measures—such as wearing long sleeves and using repellents—and community-level interventions like deer population management and habitat modification. However, the inconsistent adoption of such measures, as noted by Kugeler et al. (2015), suggests that behavioral change remains a significant barrier to prevention.

Diagnostic and treatment challenges further exacerbate the public health burden of Lyme disease. Early diagnosis is critical to preventing chronic complications, yet current serological tests are often unreliable in the initial stages of infection (Marques, 2015). Moreover, the debate over chronic Lyme disease continues to divide the medical community, leaving patients frustrated and often seeking unproven treatments. This controversy highlights the need for clearer clinical guidelines and improved patient-provider communication to build trust and ensure evidence-based care.

Co-infections add another layer of complexity. The increasing prevalence of babesiosis and anaplasmosis in Lyme-endemic areas necessitates a broader approach to tick-borne disease management (DVIDS, 2025). Clinicians must be trained to recognize the overlapping symptoms of co-infections, and surveillance systems should be adapted to track multiple pathogens simultaneously. The potential for more severe outcomes in co-infected patients also emphasizes the urgency of developing rapid, accurate diagnostic tools.

Perhaps the most glaring gap in Lyme disease control is the absence of a human vaccine. While veterinary vaccines have demonstrated efficacy in dogs, efforts to develop a human vaccine have stalled due to historical failures and public skepticism (Science Friday, 2025). Renewed investment in vaccine research, coupled with public education to address vaccine hesitancy, could provide a long-term solution to reducing Lyme disease incidence. Additionally, novel interventions such as genetically modified mice to reduce Borrelia transmission or tick-targeted pesticides show promise but require further testing and regulatory approval.

Surveillance and reporting systems also warrant improvement. The CDC’s 2022 case definition update is a step forward, but underreporting remains a persistent issue, particularly in non-endemic areas (CDC, 2024). Leveraging commercial claims data, as demonstrated by Schwartz et al. (2021), offers a potential workaround to capture a more accurate picture of disease burden. However, this approach must be standardized and integrated into national surveillance frameworks to ensure reliability and accessibility.

Recommendations

Addressing the emerging trends and public health challenges of Lyme disease in the United States requires a multifaceted approach. The following recommendations aim to strengthen prevention, surveillance, and clinical management while fostering interdisciplinary collaboration:

1. Enhance Surveillance Systems: Develop integrated surveillance platforms that monitor Lyme disease and associated co-infections across regions, incorporating both clinical and commercial claims data to improve case detection. Prioritize training for healthcare providers in non-endemic areas to recognize and report cases promptly.
2. Promote Public Education: Launch national awareness campaigns targeting high-risk and newly affected areas, focusing on personal protective measures, tick checks, and early symptom recognition. Utilize digital platforms and community outreach to ensure broad reach, particularly in underserved populations.
3. Advance Diagnostic Tools: Invest in research to develop rapid, sensitive diagnostic tests for early-stage Lyme disease and co-infections. Support clinical studies to better understand chronic Lyme disease and establish evidence-based treatment guidelines.
4. Accelerate Vaccine Development: Renew efforts to develop and commercialize a human Lyme disease vaccine, addressing past barriers such as public hesitancy through transparent communication and stakeholder engagement. Explore alternative immunization strategies, including booster shots for high-risk populations.
5. Implement Environmental Interventions: Encourage landscape management practices that reduce tick habitats, such as controlled burns and deer population control, in collaboration with local governments and environmental agencies. Support research into innovative vector control methods, like genetically engineered hosts or targeted pesticides.
6. Strengthen Policy and Funding: Advocate for increased federal and state funding for Lyme disease research, surveillance, and prevention programs. Establish interdisciplinary task forces to coordinate responses across public health, environmental, and clinical sectors.

Conclusion

Lyme disease remains a pressing public health issue in the United States, with rising incidence, geographic expansion, and complex challenges that demand urgent attention. Driven by climate change, land use patterns, and ecological shifts, the disease is no longer confined to traditional endemic areas, posing risks to a broader population. Co-infections, diagnostic limitations, and the lack of a human vaccine further complicate efforts to mitigate its impact. Through a detailed analysis of current trends and literature, this article has highlighted the need for integrated surveillance, improved diagnostics, and innovative prevention strategies. The recommendations provided offer a roadmap for public health officials, researchers, and policymakers to collaborate in reducing the burden of Lyme disease. Ultimately, addressing this evolving threat requires sustained investment, public engagement, and a commitment to adapting to changing environmental and social realities.

References

• Brownstein, J. S., Holford, T. R., & Fish, D. (2005). Effect of climate change on Lyme disease risk in North America. EcoHealth, 2(1), 38-46.
• Centers for Disease Control and Prevention (CDC). (2024). Surveillance for Lyme Disease After Implementation of a Revised Case Definition — United States, 2022. Morbidity and Mortality Weekly Report (MMWR), 73(6). Available at: https://www.cdc.gov/mmwr/volumes/73/wr/mm7306a1.htm
• Centers for Disease Control and Prevention (CDC). (2025a). Lyme Disease Surveillance and Data. Available at: https://www.cdc.gov/lyme/data-research/facts-stats/index.html
• Diuk-Wasser, M. A., Vannier, E., & Krause, P. J. (2016). Coinfection by Ixodes tick-borne pathogens: Ecological, epidemiological, and clinical consequences. Trends in Parasitology, 32(1), 30-42.
• DVIDS. (2025). Babesiosis, Lyme Disease Emerging Co-Infection Threat from Deer Ticks in Maryland. Available at: https://www.dvidshub.net/news/542329/babesiosis-lyme-disease-emerging-co-infection-threat-deer-ticks-maryland
• Environmental Protection Agency (EPA). (2025). Climate Change Indicators: Lyme Disease. Available at: https://www.epa.gov/climate-indicators/climate-change-indicators-lyme-disease
• Kugeler, K. J., Farley, G. M., Forrester, J. D., & Mead, P. S. (2015). Geographic distribution and expansion of human Lyme disease, United States. Emerging Infectious Diseases, 21(8), 1455-1457.
• LymeDisease.org. (2025). Chronic Lyme Disease: Is the Narrative Finally Shifting? Available at: https://lymedisease.org/is-lyme-narrative-finally-shifting
• Marques, A. R. (2015). Laboratory diagnosis of Lyme disease: Advances and challenges. Infectious Disease Clinics of North America, 29(2), 295-307.
• Ostfeld, R. S., Canham, C. D., Oggenfuss, K., Winchcombe, R. J., & Keesing, F. (2006). Climate, deer, rodents, and acorns as determinants of variation in Lyme-disease risk. PLoS Biology, 4(6), e145.
• Robinson, S. J., et al. (2023). The association between the incidence of Lyme disease in the USA and indicators of greenness and land cover. PMC. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10373656/
• Schwartz, A. M., et al. (2021). Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010–2018. Emerging Infectious Diseases, 27(2). Available at: https://wwwnc.cdc.gov/eid/article/27/2/20-2728_article
• Science Friday. (2025). Why Don’t We Have A Vaccine For Lyme Disease? Available at: https://sciencefriday.com/segments/lyme-disease-vaccine
• Steere, A. C., Malawista, S. E., Hardin, J. A., Ruddy, S., Askenase, P. W., & Andiman, W. A. (1977). Erythema chronicum migrans and Lyme arthritis: The enlarging clinical spectrum. Annals of Internal Medicine, 86(6), 685-698.